Predictors of Malignancy in “Pure” Branch-Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas without Enhancing Mural Nodules on CT Imaging: A Nationwide Multicenter Study
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Presence of enhanced mural nodules, which can be visualized using computed tomography (CT), is one of high-risk stigmata in branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs). Conversely, the absence of enhanced mural nodules on preoperative imaging does not exclude malignant risk. The present study aimed to investigate other morphological features as predictors of malignancy in “pure” BD-IPMNs without enhanced mural nodules on CT. Methods: This retrospective study included 180 patients with surgically confirmed “pure” BD-IPMNs of the pancreas and no enhanced mural nodules on preoperative CT. The study was conducted at 15 tertiary referral centers throughout South Korea. Univariate and multivariate analyses were used to identify significant predictors of malignancy. Results: BD-IPMNs with low-grade (n=84) or moderate-grade (n=76) dysplasia were classified as benign; those with highgrade dysplasia (n=8) or invasive carcinoma (n=12) were classified as malignant. The multivariate analysis revealed that cyst size ≥30 mm (odds ratio, 8.6; p=0.001) and main pancreatic duct diameter ≥5 mm (odds ratio, 4.1; p=0.01) were independent risk factors for malignancy in “pure” BDIPMNs without enhanced mural nodules on CT. Endoscopic ultrasound detected enhanced mural nodules (6/82) that had been missed on CT, and two IPMNs with enhanced mural nodules were malignant. Conclusions: In patients with “pure” BD-IPMNs who have no enhanced mural nodules on CT, cyst size ≥30 mm and main pancreatic duct diameter ≥5 mm may be associated with malignancy.
Abstract
Background/Aims: Presence of enhanced mural nodules, which can be visualized using computed tomography (CT), is one of high-risk stigmata in branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs). Conversely, the absence of enhanced mural nodules on preoperative imaging does not exclude malignant risk. The present study aimed to investigate other morphological features as predictors of malignancy in “pure” BD-IPMNs without enhanced mural nodules on CT. Methods: This retrospective study included 180 patients with surgically confirmed “pure” BD-IPMNs of the pancreas and no enhanced mural nodules on preoperative CT. The study was conducted at 15 tertiary referral centers throughout South Korea. Univariate and multivariate analyses were used to identify significant predictors of malignancy. Results: BD-IPMNs with low-grade (n=84) or moderate-grade (n=76) dysplasia were classified as benign; those with highgrade dysplasia (n=8) or invasive carcinoma (n=12) were classified as malignant. The multivariate analysis revealed that cyst size ≥30 mm (odds ratio, 8.6; p=0.001) and main pancreatic duct diameter ≥5 mm (odds ratio, 4.1; p=0.01) were independent risk factors for malignancy in “pure” BDIPMNs without enhanced mural nodules on CT. Endoscopic ultrasound detected enhanced mural nodules (6/82) that had been missed on CT, and two IPMNs with enhanced mural nodules were malignant. Conclusions: In patients with “pure” BD-IPMNs who have no enhanced mural nodules on CT, cyst size ≥30 mm and main pancreatic duct diameter ≥5 mm may be associated with malignancy.
참고문헌 (40)
- Furukawa T, "The mucushypersecreting tumor of the pancreas: development and extension visualized by three-dimensional computerized mapping", Cancer, 70, pp.1505~1513 (1992)[DOI]
- Kobari M, "Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management", Arch Surg, 134, pp.1131~1136 (1999)[DOI]
- Tanaka M, "International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas", Pancreatology, 6, pp.17~32 (2006)[DOI]
- Tanaka M, "International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas", Pancreatology, 12, pp.183~197 (2012)[DOI]
- Shimizu Y, "Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers", Pancreas, 42, pp.883~888 (2013)[DOI]
- Seo N, "Validation of the 2012 international consensus guidelines using computed tomography and magnetic resonance imaging: branch duct and main duct intraductal papillary mucinous neoplasms of the pancreas", Ann Surg, 263, pp.557~564 (2016)[DOI]
- Kim KW, "Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis", Ann Surg, 259, pp.72~81 (2014)[DOI]
- Jang JY, "Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms", Br J Surg, 101, pp.686~692 (2014)[DOI]
- Hirono S, "The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas", Ann Surg, 255, pp.517~522 (2012)[DOI]
- Koshita S, "Invasive carcinoma derived from flat type branch duct intraductal papillary mucinous neoplasms of the pancreas: impact of classification according to the height of mural nodule on endoscopic ultrasonography", J Hepatobiliary Pancreat Sci, 22, pp.301~309 (2015)[DOI]
- Bosman FT, "WHO classification of tumours of the digestive system", International Agency for Research on Cancer, ~ (2010)
- Harrell FE Jr, "Evaluating the yield of medical tests", JAMA, 247, pp.2543~2546 (1982)[DOI]
- Farrell JJ, "Pancreatic cystic neoplasms: management and unanswered questions", Gastroenterology, 144, pp.1303~1315 (2013)[DOI]
- Hirano S, "Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas", Hepatogastroenterology, 56, pp.515~518 (2009)
- Tanaka M, "Controversies in the management of pancreatic IPMN", Nat Rev Gastroenterol Hepatol, 8, pp.56~60 (2011)[DOI]
- Zhong N, "Histologic and imaging features of mural nodules in mucinous pancreatic cysts", Clin Gastroenterol Hepatol, 10, pp.192~198 (2012)[DOI]
- Kim TH, "Predictors of malignancy in pure branch duct type intraductal papillary mucinous neoplasm of the pancreas: a nationwide multicenter study", Pancreatology, 15, pp.405~410 (2015)[DOI]
- Sahora K, "Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series", Ann Surg, 258, pp.466~475 (2013)[DOI]
- Maguchi H, "Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan", Pancreas, 40, pp.364~370 (2011)[DOI]
- Sadakari Y, "Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules", Pancreas, 39, pp.232~236 (2010)[DOI]
- Lee T, "Natural courses of branch duct intraductal papillary mucinous neoplasm", Langenbecks Arch Surg, 402, pp.429~437 (2017)[DOI]
- Wakabayashi T, "Clinical management of intraductal papillary mucinous tumors of the pancreas based on imaging findings", Pancreas, 22, pp.370~377 (2001)[DOI]
- Yamaguchi K, "Intraductal papillary-mucinous tumor of the pancreas: assessing the grade of malignancy from natural history", Am Surg, 67, pp.400~406 (2001)
- Kim SC, "Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center", J Hepatobiliary Pancreat Surg, 15, pp.183~188 (2008)[DOI]
- Schmidt CM, "Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology", Ann Surg, 246, pp.644~651 (2007)[DOI]
- Shimizu Y, "A nomogram for predicting the probability of carcinoma in patients with intraductal papillary-mucinous neoplasm", World J Surg, 34, pp.2932~2938 (2010)[DOI]
- Ridtitid W, "Management of branchduct intraductal papillary mucinous neoplasms: a large singlecenter study to assess predictors of malignancy and long-term outcomes", Gastrointest Endosc, 84, pp.436~445 (2016)[DOI]
- Tanaka M, "Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas", Pancreatology, 17, pp.738~753 (2017)[DOI]
- Kobayashi G, "Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules: a Japan Pancreas Society multicenter study", Pancreas, 43, pp.532~538 (2014)[DOI]
- Kawada N, "Predictors of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas", JOP, 15, pp.459~464 (2014)
- Ohno E, "Malignant transformation of branch duct-type intraductal papillary mucinous neoplasms of the pancreas based on contrast-enhanced endoscopic ultrasonography morphological changes: focus on malignant transformation of intraductal papillary mucinous neoplasm itself", Pancreas, 41, pp.855~862 (2012)[DOI]
- Kurihara N, "Vascular patterns in nodules of intraductal papillary mucinous neoplasms depicted under contrast-enhanced ultrasonography are helpful for evaluating malignant potential", Eur J Radiol, 81, pp.66~70 (2012)[DOI]
- Vege SS, "American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts", Gastroenterology, 148, pp.819~822 (2015)[DOI]
- Yamaguchi K, "Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas", Pancreatology, 2, pp.484~490 (2002)[DOI]
- Uehara H, "Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas", Gut, 57, pp.1561~1565 (2008)[DOI]
- Ingkakul T, "Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas", Ann Surg, 251, pp.70~75 (2010)[DOI]
- Tanno S, "Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms", Pancreas, 39, pp.36~40 (2010)[DOI]
- Tanno S, "Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm", Pancreatology, 10, pp.173~178 (2010)[DOI]
- Ideno N, "Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma", Pancreas, 44, pp.311~320 (2015)[DOI]
- Rockacy M, "Update on pancreatic cyst fluid analysis", Ann Gastroenterol, 26, pp.122~127 (2013)
